Deus Technologies got the nod from the FDA to begin selling its RapidScreen RS-2000 to assist in the detection of early-stage lung cancer. The computer-assisted detection system digitizes and analyzes chest radiographs to identify regions of interest
Deus Technologies got the nod from the FDA to begin selling its RapidScreen RS-2000 to assist in the detection of early-stage lung cancer. The computer-assisted detection system digitizes and analyzes chest radiographs to identify regions of interest that may have features associated with early-stage lung cancer. The system uses image enhancement and pattern recognition techniques to locate suspicious areas that may warrant a second review by a radiologist. Deus developed the software using thousands of existing chest images as training data sets. The software contains elements of artificial neural networks and fuzzy logic technology.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.